Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
December 20, 2021 07:00 ET
|
Cara Therapeutics, Inc.
KORSUVA receives TDAPA reimbursement beginning April 2022 U.S. commercial launch on track for early second quarter 2022 STAMFORD, Conn., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics,...
Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 18, 2021 08:30 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical...
Cara Therapeutics to Present at Upcoming Investor Conferences
November 09, 2021 16:30 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Reports Third Quarter 2021 Financial Results
November 08, 2021 16:01 ET
|
Cara Therapeutics, Inc.
– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug...
Cara Therapeutics Announces CEO Transition
November 03, 2021 08:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021
November 01, 2021 16:15 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
October 04, 2021 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
September 29, 2021 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 24, 2021 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
August 23, 2021 15:41 ET
|
Cara Therapeutics, Inc.
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in...